HTBA has over 200 employees and is headquartered in Barcelona, Spain. It has a production plant in Beniel, Murcia, Spain, and a subsidiary in Cincinnati, Ohio, US. Leveraging its pharmaceutical background, its product and process innovation capabilities and its state-of-the-art manufacturing facilities, the company has developed strong and longstanding relationships with clients in more than 60 countries around the world.

LGT Private Debt was already familiar with HTBA from a previous transaction. In 2019, the firm supported The Riverside Company’s acquisition of HTBA when it was formed from the carve-out of Grupo Ferrer.

Kevin Abrial, Partner at LGT Capital Partners, said: “We are pleased to once again support Miura Partners and HTBA as the company embarks on its next phase of growth. We believe that HTBA is well positioned to accelerate its expansion, building on its solid position in the pharma flavonoid segment on the back of its strong development over the past few years.”

Private debt is one of LGT Capital Partners’ areas of expertise in the field of private markets. The team has an average of 13 years of industry experience and is based in Paris, London and Frankfurt am Main. It has invested more than EUR 5.9 billion since 2005. As a specialist in the European private debt market, it arranged the first unitranche transaction in Europe in 2007.